本文選題：利他唑酮 + 利奈唑胺��； 參考：《中國抗生素雜志》2016年11期

【摘要】：目的研究利他唑酮(LT-01)注射劑對小鼠細(xì)菌感染的保護(hù)作用,以此來評價LT-01的體內(nèi)抗菌效果。方法用LT-01注射劑及利奈唑胺注射液對2株革蘭陽性菌感染小鼠敗血癥模型進(jìn)行保護(hù)作用研究,記錄小鼠的存活數(shù),并用DAS2.1.1軟件計算半數(shù)有效量(ED_(50))等參數(shù),并比較兩藥的差異。結(jié)果 LT-01注射劑對萬古霉素耐藥腸球菌(VRE)感染小鼠敗血癥模型的ED_(50)=1.036mg/kg,對耐甲氧西林金黃色葡萄球菌(MRSA)感染小鼠敗血癥模型ED_(50)=1.271mg/kg,與市售利奈唑胺注射液相比均無顯著差異(P0.05)。結(jié)論實(shí)驗(yàn)結(jié)果表明LT-01對革蘭陽性球菌有很好的抗菌作用,提示LT-01是一種可用于臨床治療耐藥革蘭陽性球菌感染的藥物,值得進(jìn)一步開發(fā)研究。
[Abstract]:Objective to study the protective effect of Ritazolone LT-01) injection on bacterial infection in mice and evaluate the antibacterial effect of LT-01 in vivo. Methods the protective effects of LT-01 injection and linazolamide injection on the septicemia model of two Gram-positive bacteria infected mice were studied. The survival number of mice was recorded and the parameters such as half effective dose (LD50) were calculated by DAS2.1.1 software and the difference between the two drugs was compared. Results the septicemia model of mice infected with vancomycin resistant enterococci and methicillin-resistant staphylococcus aureus infected with LT-01 injection was 1.036 mg / kg and 1.271 mg / kg respectively. Conclusion the experimental results show that LT-01 has a good antibacterial effect on Gram-positive cocci, suggesting that LT-01 is a drug that can be used in clinical treatment of drug-resistant Gram-positive cocci infection, and it is worthy of further development and study.
【作者單位】： 解放軍第三0二醫(yī)院藥學(xué)部藥物臨床試驗(yàn)中心;北京大學(xué)第一醫(yī)院臨床藥理研究所;四川賽卓藥業(yè)股份有限公司;
【基金】：國家十二五重大新藥創(chuàng)制 國家重大科技專項課題(No.2014ZX09201001-008)
【分類號】：R965
，

本文編號：1934216